Objectives: Dactylitis is an important clinical domain of psoriatic arthritis (PsA) associated with significant burden of disease and impaired function. Post-hoc analysis of the FUTURE 5 study was performed to evaluate the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.
Methods: Randomised patients received secukinumab 300mg with loading dose (LD)/150mg LD/150mg without loading dose/placebo. Assessment of dactylitis was based on Leeds Dactylitis Index. Exploratory analyses included resolution of dactylitis based on severity, time to first resolution of dactylitis (Kaplan-Meier estimate) and resolution of dactylitis (heatmap analysis). Clinical efficacy outcomes, composite domains of disease activity, health-related quality of life (HRQoL) and radiographic progression using van der Heijde-modified total Sharp score were assessed in patients with/without dactylitis at baseline.
Results: Overall, 389/996 (39%) patients presented with dactylitis at baseline, had more active clinical disease and greater disease activity than those without dactylitis at baseline. Resolution of dactylitis was observed across all treatment groups at Week 104. Improvement in joints, enthesitis, skin psoriasis, nail outcomes, physical function and HRQoL were sustained over 2 years in patients with dactylitis at baseline. With secukinumab treatment, >80% of patients did not show structural radiographic progression. The proportion of non-structural radiographic progressors were comparable across patients with/without dactylitis at baseline with secukinumab treatment over 2 years.
Conclusions: Patients with dactylitis at baseline were associated with higher burden of disease. Secukinumab provided sustained improvements across all clinical outcomes, QoL and inhibition of radiographic progression in PsA patients with dactylitis at baseline over 2 years.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.55563/clinexprheumatol/vezf95 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Value of ultrasound-assessed dactylitis in the early diagnosis of psoriatic arthritis.
Semin Arthritis Rheum
February 2025
Department of Rheumatology and Joint and Bone Research Unit. Fundación Jiménez Díaz University Hospital and Health Research Institute Fundación Jiménez Díaz (IIS-FJD, UAM), Autonomous University of Madrid, Madrid, Spain. Electronic address:
Purpose: The primary objective of this prospective, longitudinal, observational, single-centre study was to evaluate the association between ultrasound-assessed lesions of dactylitis and the diagnosis of psoriatic arthritis (PsA) in patients with psoriasis (PsO) and hand arthralgia.
Methods: We included adult patients diagnosed with PsO with hand arthralgia, with or without other musculoskeletal complaints. They were clinically assessed at baseline, 6 and 12 months by a rheumatologist blinded to the ultrasound findings.
Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial.
RMD Open
December 2024
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Objectives: To prospectively evaluate the effect of guselkumab through 48 weeks across various clinical outcomes in subgroups of patients with psoriatic arthritis (PsA) and inadequate response to tumour necrosis factor inhibitors (TNFi-IR) from the phase 3b COSMOS trial. Subgroups were defined by baseline demographics, disease characteristics and prior/ongoing therapies.
Methods: Patients with active PsA (tender joint count (TJC) and swollen joint count (SJC) both ≥3) and TNFi-IR were randomised 2:1 to receive guselkumab 100 mg at week 0, week 4, then every 8 weeks through week 44 or to placebo with cross-over to guselkumab 100 mg at week 16 (early escape) or week 24 (planned).
Characteristics That Predict Psoriatic Arthritis by the Classification Criteria for Psoriatic Arthritis in Patients With Juvenile Idiopathic Arthritis 18 Years After Disease Onset.
ACR Open Rheumatol
January 2025
Uppsala University, Uppsala, Sweden.
Article Synopsis
- The study aimed to evaluate patients with juvenile idiopathic arthritis (JIA) to see how many fit the criteria for psoriatic arthritis (PsA) 18 years after the disease began.
- Of the 510 initially enrolled patients, only 434 participated in follow-up, with 9.4% meeting the CASPAR criteria for PsA, indicating CASPAR may be more effective in identifying these patients than the ILAR criteria.
- Key predictors for developing PsA included specific joint involvement at disease onset and the presence of psoriasis, nail abnormalities, or dactylitis, with dactylitis being the strongest predictor.
No difference in clinical parameters and drug retention in PsA patients receiving b/tsDMARD monotherapy versus combination with methotrexate: data from the RABBIT-SpA registry.
RMD Open
July 2024
Epidemiology Unit, German Rheumatism Research Center Berlin, Berlin, Germany.
Background: The potential benefit of methotrexate (MTX) in combination with biologic (b) and targeted synthetic (ts) disease modifying anti-rheumatic drugs (DMARDs) in psoriatic arthritis (PsA) is still a matter of debate.
Objectives: To compare clinical and patient reported characteristics as well as drug retention rates in PsA patients receiving b/tsDMARD monotherapy or in combination with MTX.
Methods: RABBIT-SpA is a prospective longitudinal cohort study including axSpA and PsA patients.
Initiation of vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24-week study with imaging assessments.
United European Gastroenterol J
September 2024
Lawson Health Research Institute, London, Ontario, Canada.
Article Synopsis
- - The study aimed to explore if starting vedolizumab (a medication for inflammatory bowel disease) was linked to new-onset spondyloarthritis (SpA) in patients with IBD through clinical evaluations and MRIs.
- - 24 patients with active ulcerative colitis or Crohn's disease participated, with assessments made before starting treatment and at 8 and 24 weeks.
- - Results showed that none of the patients developed new forms of axial or peripheral SpA after 24 weeks, indicating that vedolizumab does not appear to trigger these conditions in either TNF inhibitor-naïve or experienced patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!